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Available online 6 January 2011AbstractAim: Near-infrared (NIR) fluorescence optical imaging is a promising technique to assess the extent of colorectal metastases during cura-
tive-intended surgery. However, NIR fluorescence imaging of liver metastases is highly challenging due to hepatic uptake and clearance of
many fluorescent dyes. In the current study, the biodistribution and the ability to demarcate liver and peritoneal metastases were assessed
during surgery in a syngeneic rat model of colorectal cancer using an integrin avb3-directed NIR fluorescence probe.
Methods: Liver tumors and peritoneal metastases were induced in 7 male WAG/Rij rats by subcapsular inoculation of 0.5  106 CC531
colorectal cancer rat cells into three distinct liver lobes. Intraoperative and ex vivo fluorescence measurements were performed 24
(N ¼ 3 rats, 7 tumors) and 48 h (N ¼ 4 rats, 9 tumors) after intravenous administration of the integrin avb3-directed NIR fluorescence probe.
Results: Colorectal metastases had a minimal two-fold higher NIR fluorescence signal than healthy liver tissue and other abdominal organs
( p < 0.001). The tumor-to-background ratio was independent of time of imaging (24 h vs. 48 h post-injection; p ¼ 0.31), which facilitates
flexible operation planning in future clinical applications. Total fluorescence intensity was significantly correlated with the size of metas-
tases (R2 ¼ 0.92 for the 24 h group, R2 ¼ 0.96 for the 48 h group).
Conclusion: These results demonstrate that colorectal intra-abdominal metastases can be clearly demarcated during surgery using an integ-
rin avb3 targeting NIR fluorescence probe. Translating these findings to the clinic will have an excellent potential to substantially improve
the quality of cancer surgery.
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Survival of colorectal cancer patients is largely restricted
by the occurrence of metastases, predominantly in the liver.
In the course of the disease, up to 50% of patients willAbbreviation: NIR, near-infrared.
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0748-7983  201 Elsevier Ltd. Open access under the Elsevier OA license.0eventually develop liver metastases.1 If confined to the
liver, surgery offers a possible curative treatment option
with 5-year survival rates of 35e40%.2 However, at the
time of surgery, adequate assessment of the extent of the
disease is still limited, resulting in a 40e50% recurrence
rate.3 Clearly, innovative visualization techniques are
needed to facilitate intraoperative assessment of the extent
of the cancer tissue and to guide the subsequent surgical re-
moval of these tumors with adequate margins in an attempt
to increase the complete resection rate.
Real-time visualization of cancer cells using near-infra-
red (NIR) fluorescence optical imaging is a promising tech-
nique to assess the extent of colorectal metastases during
253M. Hutteman et al. / EJSO 37 (2011) 252e257curative-intended surgery.4e6 However, optical imaging of
liver metastases is highly challenging due to the high
absorptivity of liver tissue for visble light and hepatic up-
take and clearance of many fluorescent dyes.7,8 Recent
studies demonstrated successful identification of breast,
lung and glioblastoma cancers by targeting a member of
the integrin family, integrin avb3.
9e13 Integrins are cell-sur-
face transmembrane heterodimeric glycoproteins that are
involved in cell adhesion, matrix interaction and cell signal-
ing pathways. Integrin avb3 plays a key role in the early
phase of tumor angiogenesis, tumor cell migration and is
overexpressed in various cancer types, including colorectal
cancer.14e17 Because hepatocytes show little expression of
integrin avb3,
16,18 it is expected that NIR fluorescence
probes targeting integrin avb3 result in little background
in the liver.9 Therefore, the aim of this study was to inves-
tigate the biodistribution and the ability to clearly demar-
cate liver and peritoneal metastases during surgery in
a syngeneic rat model of colorectal cancer using an integrin
avb3-directed NIR fluorescence probe.
Materials and methodsAnimal modelRat CC531 colorectal cancer cells were cultured in
RPMI 1640 supplemented with 2 mM L-glutamine (Gibco,
Invitrogen Ltd, Carlsbad, USA), 10% heat-inactivated fetal
calf serum, 100 U/ml penicillin and 0.1 mg/ml streptomy-
cin sulphate.19 In order to induce liver and peritoneal me-
tastases, CC531-syngeneic male WAG/Rij rats (Charles
River, Maastricht, the Netherlands) weighing 300e350 g
underwent median laparotomy and the liver was exposed.
Subsequently, 500,000 CC531 cells (50 ml) were subcapsu-
larly inoculated into the left and right main liver lobes, and
the right accessory liver lobe.19 To prevent tumor spill,
puncture sites were covered with a small sponge, directly
after tumor cell injection. Four weeks after inoculation, me-
tastases of approximately 5 mm in diameter had originated
in the liver. The Animal Welfare Committee of the Leiden
University Medical Center approved the experiments.NIR fluorescence probeThe NIR fluorescence probe IntegriSense680 (VisEn
Medical, Woburn, USA) with peak absorbance at 680 nm
was used for fluorescence imaging. IntegriSense680 con-
sists of a small non-peptide integrin avb3 antagonist,
20
which is conjugated to the NIR fluorescence probe Viv-
oTag-S680 (VisEn Medical).Intraoperative NIR fluorescence camera systemThe Fluobeam system (Fluoptics, Grenoble, France)
was used for these experiments and has been described pre-
viously.21 In short, the Fluobeam system is composed ofa 100 mW laser emitting at 690 nm with an illumination
power of 2.6 mW/cm2 and a 12-bit CCD camera. The ani-
mal is placed under the laser and illuminated by white light
filtered with a band-pass filter (350e650 nm) providing an
irradiance of 7  103 lx at the animal level.Animal experimentsAll animalswere housed in the animal facility of theLeiden
University Medical Center. Pellet food and fresh tap water
were provided ad libitum. The weight of the animals was fol-
lowed throughout the experiment to monitor their general
health state. Throughout tumor inoculation, imaging and sur-
gical procedures, the animals were anesthetized with 5% iso-
flurane for induction and 2% isoflurane for maintenance in
oxygen with a flow of 0.8 L/min and placed on an animal
bed with an integrated nose mask. Rats (N¼ 7) were injected
intravenously into the penile vein with IntegriSense680
(12 nmol per animal) 24 h (3 rats, N ¼ 7 tumors) or 48 h (4
rats, N ¼ 9 tumors) before imaging. These time points were
chosen based on the blood pharmacokinetics of Integri-
Sense680 (VisEn website: www.visenmedical.com). Before
injection, the level of autofluorescencewas determined ofme-
tastases, surrounding tissue and abdominal organs. During in-
traoperativeNIRfluorescence imaging ofmetastases amedian
laparotomy was performed followed by a systematic explora-
tion of the peritoneal cavity. After intraoperative imaging,
livers containingmetastaseswere completely excised for addi-
tional ex vivo fluorescencemeasurements. Peritonealmetasta-
ses identified clinically or by fluorescence were carefully
excised. Fluorescence intensity of metastases and abdominal
organswas determined invivo and ex vivo using the Fluobeam
system. After resection, tumors were imaged ex vivo using the
IVIS Spectrum (Caliper LifeSciences, Hopkinton, USA),
which allowed isolation of the IntegriSense680 signal from
the backgroundfluorescence bymeansof spectral unmixing.22MicroscopyExcised tumors were fixed in 10%buffered formalin over-
night and washed in 70% ethanol. Following paraffin embed-
ding and mounting, tissue sections specimens of 4 mm were
air-dried and stained with standard hematoxylin-eosin. In
parallel, freshly excised liver lobes containing tumors were
processed for fluorescence microscopy. Fresh tumors and
surrounding liver tissue blocks of approximately 2 cm in di-
ameter were incubated with 0.5 ml phalloidin-Alexa Fluor
488 (0.5 mM) and Hoechst 33342 (48 mM; both from Invitro-
gen) for 1 h at room temperature to stain the F-actin filaments
in particular those of the cell membrane of hepatocytes,23 and
the dsDNA at the cell nucleus, respectively. Tumors were
placed in glass-bottom Petri dish (P35G-1.5-14-C, Mattek
Corporation, Ashland, USA) and analyzed using the Leica
TCS SP5 inverted confocal microscope (Leica Microsys-
tems, Wetzlar, Germany; HCX PL APO 40x; N.A. 1.25 oil
immersion objective). Hoechst, phalloidin-AlexaFluor488
254 M. Hutteman et al. / EJSO 37 (2011) 252e257and IntegriSense680 were excited by a 405 nm diode,
a 488 nmArgon laser and a 633 HeNe nm laser, respectively.
The 12-bit images were analyzed using the Leica LAS AF
software and the three signals were pseudo-colored with
blue for Hoechst, green for phalloidin-AlexaFluor488, and
red for IntegriSense680.Statistical analysisFluobeam derived NIR fluorescence data were analyzed
using the open-source software ImageJ24 by drawing regions
of interest at the tumor and at the surrounding tissue within
a range of 2 mm of the demarcation line of the tumor and
the surrounding tissue by visual interpretation andmeasuring
the fluorescent intensity of the 12-bit images.Merged images
of visible light images and NIR fluorescence light images
generated by the Fluobeam systemwere created usingAdobe
Photoshop CS3 Software (version 10.0.1, Adobe Systems
Inc., San Jose, USA). IVIS Spectrum derived NIR fluores-
cence data were analyzed using LivingImage software (ver-
sion 3.2, Caliper LifeSciences, Hopkinton, USA) using the
methods described above. Statistical analysis and generation
of graphs were performed using GraphPad Prism Software
(version 5.01, La Jolla, USA). Mean fluorescence intensity
and associated standard deviations were reported. Unpaired
and paired t-tests were used for testing differences of fluores-
cence intensity between groups. Pearson’s correlation coeffi-
cients were calculated for the analysis of the size of tumors
and the total fluorescence intensity. Statistical tests were
two-tailed and p < 0.05 was considered significant.
ResultsIntraoperative detection of colorectal liver metastasesIn a total of 7 rats, all colorectal liver metastases (N ¼ 16)
were identified during surgery with the intraoperative Fluo-
beam camera system after targeting of integrinavb3 expression
with IntegriSense680 (Fig. 1A). Quantification of the NIRFigure 1. NIR fluorescence detection of colorectal liver metastases using Integri
CC531 colorectal liver metastasis in a male rat 24 h after injection of 12 nmol In
signal of colorectal liver metastases and healthy liver tissue is plotted for rats injec
rats, 9 tumors). P values represent paired t-test comparisons. C. Tumor-to-backg
48 h. There was no significant difference between the groups (unpaired t-test, tfluorescence signal was performed using spectral unmixing
with the IVIS Spectrum, enabling separation of true Integri-
Sense680 signal from background fluorescence. The NIR fluo-
rescence signal was significantly higher in the colorectal
metastases in comparison to healthy liver tissue, regardless of
the rats were imaged 24 h after injection (N ¼ 7, paired
t ¼ 10.8, p < 0.0001) or 48 h after injection (N ¼ 9, paired
t ¼ 6.59, p ¼ 0.0002; Fig. 1B). The NIR fluorescence signal
of the colorectal metastases was on average two-fold higher
than that of the healthy liver and the tumor-to-background ratio
was not significantly different when comparing the 24 h (mean
TBR ¼ 2.04) and 48 h group (mean TBR ¼ 1.81, unpaired
t ¼ 1.06, p ¼ 0.31; Fig. 1C). Total fluorescence intensity was
significantly correlated with the size of metastases
(R2 ¼ 0.92 for the 24 h group, R2 ¼ 0.96 for the 48 h group).
Measurements on the IVIS Spectrum were in concordance
with the visual information provided by the Fluobeam system
(data not shown). Sectioning of tumor and liver tissue showed
a clear demarcation of fluorescence signal at the tumor border,
which was confirmed by fluorescence microscopy (Fig. 2).Biodistribution of IntegriSense680To assess the potential use of IntegriSense680 in intrao-
perative identification of colorectal metastases in close
proximity to other organs in the peritoneal cavity, the
NIR fluorescence intensity of abdominal organs was quan-
tified 24 and 48 h after injection of IntegriSense680 using
the Fluobeam system (Fig. 3). All abdominal organs
showed fluorescence intensity levels comparable to or
lower than the liver. No difference was observed between
measurements at 24 and 48 h after injection.Intraoperative detection of intra-peritonealmetastasesThe sufficiently low fluorescence levels of abdominal
organs suggest a potential use of IntegriSense680 for identifica-
tion of peritoneal colorectalmetastases. In all animals, the peri-
toneal cavity was carefully inspected for tumor deposits. InSense680: A. Intraoperative NIR fluorescence detection of a 1.2  5 mm
tegriSense680. Camera exposure time was 15 ms. B. The NIR fluorescence
ted with IntegriSense680 after 24 h (N ¼ 3 rats, 7 tumors) and 48 h (N ¼ 4
round ratio is plotted for rats injected with IntegriSense680 after 24 h and
¼ 1.06, p ¼ 0.31).
Figure 2. Ex vivo NIR fluorescence imaging of a colorectal liver metastasis: Shown are a color image (left), a NIR fluorescence image (middle left), and
a pseudo-colored green merge (middle right) of a 0.9  1.8 cm CC531 colorectal liver metastasis within an excised liver lobe. Imaging was performed 48 h
after injection of 12 nmol IntegriSense680. Camera exposure time was 10 ms. The distance between two major ruler ticks is 1 cm. Ex vivo fluorescence
microscopy (right) of a freshly resected liver lobe containing a CC531 colorectal liver metastasis after incubation with Hoechst (dsDNA, pseudo-colored
blue) and phalloidin-AlexaFluor488 (F-actin filaments, pseudo-colored green). The IntegriSense680 signal is pseudo-colored red. The dashed line indicates
the transition zone between the normal liver (left bottom corner) and the liver tumor (right upper corner).
255M. Hutteman et al. / EJSO 37 (2011) 252e257several animals, several suspected tumors were found in the
mesentery (Fig. 4). These nodules were fluorescent and were
confirmed asmalignancies by histological analyses. Total fluo-
rescence was significantly correlated with the size of mesente-
rial metastases (R2 ¼ 0.99). No clinically evident intra-
abdominal tumordepositswithoutfluorescencewere observed.DiscussionNIR fluorescence imagingWe have demonstrated the potential use of the NIR fluo-
rescence probe IntegriSense680 for intraoperative tumor
identification in both colorectal metastases confined to the
liver and metastases elsewhere in the peritoneal cavity. To
our knowledge, the current study is the first study on targeting
liver metastases using a targeted NIR fluorophore. NIR fluo-
rescence imaging within the peritoneal cavity is often ham-
pered by high levels of background fluorescence. Despite
these difficulties, IntegriSense680 provided an adequateT
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Figure 3. In vivo biodistribution of IntegriSense680: Fluorescence intensity
of colorectal CC531 liver tumors and abdominal organs was measured
using the Fluobeam camera system in two rats before (level of autofluor-
escence), 24 h and 48 h after administration of 12 nmol IntegriSense680.
Camera exposure time was 10 ms. Bars represent mean  SD.tumor-to-background ratio to identify tumors in the vicinity
of abdominal organs. The targeting ligand of Integri-
Sense680 is a non-peptide integrin avb3 antagonist that is de-
rived from the full-length RGD tripeptide.20 This non-
peptide molecule has a significantly improved affinity in
comparison with the full-length RGD peptides, which have
been used in imaging studies.10,25e27 No difference was ob-
served between imaging 24 h post administration and imag-
ing 48 h post administration. This broad window of
intraoperative imaging facilitates flexible operation planning
in future clinical applications.Peritoneal metastasesIn the current study, we were able to detect both liver
and peritoneal metastases. Although the model is set up
as a liver tumor model, some rats also developed peritoneal
metastases, particularly those bearing larger liver tumors.
Peritoneal spreading of tumor cells could have derived
from tumor spill during the inoculation procedure or
“real” metastases from large liver tumors.28 Although this
may be a biologically relevant difference, it possesses no
alteration for the purpose of the current study. During the
experiments, no clinically evident intra-abdominal or lung
metastases were found that were not NIR fluorescent.
It is well known that small metastases can easily be
missed on preoperative imaging studies, as CT or MRI. Pre-
viously, a minimal detectable number of tumor cells of ap-
proximately 13,000 was reported with the CC531 colorectal
cancer cell line and NIR fluorescence imaging,21 reflecting
submillimeter tumor depositions. NIR fluorescence imag-
ing could therefore potentially be used in the clinic as an
adjunct to preoperative staging, for intraoperative detection
of metastases that were not observed on preoperative tumor
dissemination imaging.Clinical implicationsIntegrin avb3 as a targeting ligand has been studied exten-
sively in a preclinical setting.18,29,30 Several clinical studies
Figure 4. NIR fluorescence imaging of colorectal CC531mesenterial metastases using IntegriSense680 and the intraoperative camera system: Shown are a color
image (top left), a NIRfluorescence image (topmiddle), and a pseudo-colored greenmerge of the two images (top right) of a part of the jejunumand accompanied
mesentery of a rat bearingmultiple CC531mesenterialmetastases. AeE indicate suspectedmetastases, LN indicatesmesenteric lymph nodes,Neg indicates area
selected as negative control. Imagingwas performed 24 h after injection of 12 nmol IntegriSense680.Camera exposure timewas 20ms. The distance between two
major ruler ticks is 1 cm. H&E staining (bottom left) of a 4 mm formalin-fixed, paraffin-embedded tissue section of the metastasis indicated by B (dashed square,
top right). The size, NIR fluorescence measurements and presence of tumor cells of the indicated regions (top right) are tabulated at the bottom right panel. Total
NIRF is the total NIR fluorescence signal of the region-of-interest. Average NIRF is the total NIR fluorescenFce signal of the region-of-interest divided by the
area. Total NIR fluorescence was significantly correlated with the size of the metastases (R2 ¼ 0.99).
256 M. Hutteman et al. / EJSO 37 (2011) 252e257have been performed using integrinavb3 as a target for radio-
immunotherapy in breast cancer and glioblastoma pa-
tients.11,25 Although radiotracers are potentially useful for
diagnosis and treatment by means of radioimmunotherapy,
their applicability during surgery is limited due to a lack of
intraoperative visualization of the tracer. Nonetheless, these
studies suggest a successful introduction of integrin avb3 as
a targeting ligand for NIR fluorescence image-guided sur-
gery in the clinic, which will enable real-time, intraoperative
visualization of tumor cells. A major hurdle to be taken is
clinical approval of novel NIR fluorophores. Currently, in-
docyanine green and methylene blue are the sole NIR fluoro-
phores available for clinical applications. Both compounds
have suboptimal properties for intraoperative applications
and both are not easily conjugated to a targeting ligand. Ishi-
zawa and colleagues have demonstrated the possibility of in-
traoperative identification of colorectal liver metastases after
intravenous injection of indocyanine green.31 In this study,
colorectal liver metastases displayed a fluorescence pattern
described as “rim fluorescence”, where the tumor itself is
not fluorescent, but the surrounding liver tissue is. Ishizawaet al suggest that this is caused by decreased biliary excretion
of indocyanine green around the tumor.Whereas this is an in-
teresting observation for the detection of hepatic colorectal
metastases, themechanism exploited for this purpose (biliary
excretion) prevents this from being used for extra-hepatic in-
tra-abdominal colorectal metastases. This is of particular im-
portance, as the detection of extra-hepatic metastases is
a determining factor for clinical decision making. Further-
more, the efficacy of this probe for tumor imaging is strongly
dependent on biliary excretion and liver function, limiting its
applicability in some patients. Many research groups are
working on advancing novel NIR fluorescence fluorophores
to the clinic.When these agents become available for clinical
testing, NIR fluorescence image-guided surgerywill have the
potential to greatly improve surgical practice and patient
outcome.
Conclusion
NIR fluorescence image-guided surgery has the potential
to improve surgical oncology by addressing one of its most
257M. Hutteman et al. / EJSO 37 (2011) 252e257fundamental challenges, the complete and en bloc resection
of tumors. The current study demonstrates the feasibility of
employing a novel NIR fluorescence contrast agent, Integri-
Sense680, for the intraoperative detection of colorectal me-
tastases in a syngeneic rat model. Clinical translation of
NIR fluorescence agents such as IntegriSense680 is pivotal
for improving the quality of cancer surgery.
Conflict of interest
None.Acknowledgements
We want to thank Fluoptics (Grenoble, France) for pro-
viding us with the Fluobeam system to perform the above
described experiments and Gabi van Pelt and Karien de
Rooij for technical assistance.
This study was performed within the framework of
CTMM, the Center for Translational Molecular Medicine
(DeCoDe project, grant 03O-101). This study was sup-
ported by the Sacha Swarttouw-Hijmans Foundation.
J.S.D. Mieog is a MD-medical research trainee funded by
The Netherlands Organisation for Health Research and
Development (grant nr. 92003526).References
1. McMillan DC, McArdle CS. Epidemiology of colorectal liver metas-
tases. Surg Oncol 2007;16:3–5.
2. Ruers T, Bleichrodt RP. Treatment of liver metastases, an Update on
the Possibilities and results. Eur J Cancer 2002;38:1023–33.
3. Finch RJ, Malik HZ, Hamady ZZ, et al. Effect of type of resection on
outcome of hepatic resection for colorectal metastases. Br J Surg
2007;94:1242–8.
4. Frangioni JV. New technologies for human cancer imaging. J Clin On-
col 2008;26:4012–21.
5. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology.
Nature 2008;452:580–9.
6. TeVeldeEA,VeermanT, SubramaniamV,Ruers T. The use of fluorescent
dyes and probes in surgical oncology. Eur J Surg Oncol 2010;36:6–15.
7. Blum G, Weimer RM, Edgington LE, Adams W, Bogyo M. Compar-
ative assessment of substrates and activity based probes as tools for
non-invasive optical imaging of Cysteine Protease Activity. PLoS
One 2009;4:e6374.
8. Frangioni JV. The problem is background, not signal. Mol Imaging
2009;8:303–4.
9. Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ. An
open-label, multicenter, phase 2a study to assess the feasibility of im-
aging metastases in Late-Stage cancer patients with the alpha(v)beta
(3)-Selective angiogenesis imaging agent (99m)Tc-NC100692. Acta
Radiol 2010;51:40–6.
10. Edwards WB, Akers WJ, Ye Y, et al. Multimodal imaging of integrin
receptor-positive tumors by bioluminescence, fluorescence, gamma
scintigraphy, and single-photon emission computed tomography using
a cyclic RGD peptide labeled with a near-infrared fluorescent dye and
a radionuclide. Mol Imaging 2009;8:101–10.11. Beer AJ, Niemeyer M, Carlsen J, et al. Patterns of alphavbeta3 expres-
sion in primary and metastatic human breast cancer as shown by 18F-
Galacto-RGD PET. J Nucl Med 2008;49:255–9.
12. Wu Y, Cai W, Chen X. Near-Infrared fluorescence imaging of tumor
integrin alpha v beta 3 expression with Cy7-labeled RGD multimers.
Mol Imaging Biol 2006;8:226–36.
13. Chen X, Hou Y, Tohme M, et al. Pegylated Arg-Gly-Asp peptide:
64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin
expression. J Nucl Med 2004;45:1776–83.
14. Hood JD, Cheresh DA. Role of integrins in cell invasion and migra-
tion. Nat Rev Cancer 2002;2:91–100.
15. Vonlaufen A, Wiedle G, Borisch B, et al. Integrin alpha(v)beta(3) ex-
pression in colon carcinoma correlates with survival. Mod Pathol
2001;14:1126–32.
16. Merono A, Lucena C, Lopez A, et al. Immunohistochemical analysis
of Beta3 integrin (CD61): expression in pig tissues and human tumors.
Histol Histopathol 2002;17:347–52.
17. Le Tourneau C, Faivre S, Raymond E. The role of integrins in colorec-
tal cancer. Oncol (Williston Park) 2007;21:21–4.
18. Dijkgraaf I, Beer AJ, Wester HJ. Application of RGD-containing pep-
tides as imaging probes for alphavbeta3 expression. Front Biosci 2009;
14:887–99.
19. Vahrmeijer AL, van Dierendonck JH, Schutrups J, van de Velde CJ,
Mulder GJ. Potentiation of the cytostatic effect of Melphalan on Co-
lorectal cancer hepatic metastases by infusion of Buthionine Sulfoxi-
mine (BSO) in the rat: enhanced tumor Glutathione depletion by
infusion of BSO in the hepatic artery. Cancer Chemother Pharmacol
1999;44:111–6.
20. Coleman PJ, Brashear KM, Askew BC, et al. Nonpeptide alphavbeta3
antagonists. Part 11: discovery and preclinical evaluation of potent al-
phavbeta3 antagonists for the prevention and treatment of osteoporo-
sis. J Med Chem 2004;47:4829–37.
21. Mieog JS, Vahrmeijer AL, Hutteman M, et al. Novel intraoperative
near-infrared fluorescence camera system for optical image-guided
cancer surgery. Mol Imaging 2010;9:223–31.
22. Mansfield JR, Hoyt C, Levenson RM. Visualization of microscopy-
based spectral imaging data from multi-label tissue sections. Curr
Protoc Mol Biol 2008;. [Chapter 14]:Unit.
23. Wieland T, Faulstich H. Amatoxins, phallotoxins, phallolysin, and an-
tamanide: the biologically active components of poisonous amanita
mushrooms. CRC Crit Rev Biochem 1978;5:185–260.
24. Rasband WS. ImageJ. Bethesda, Maryland, USA: U. S. National Insti-
tutes of Health; 2009.http://rsb.info.nih.gov/ij/.
25. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography
using [18F] Galacto-RGD identifies the level of integrin alpha(v)
beta3 expression in man. Clin Cancer Res 2006;12:3942–9.
26. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence im-
aging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res
2004;64:8009–14.
27. Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin alpha(v)beta
(3) expression in patients with malignant glioma by [18F] Galacto-
RGD Positron Emission Tomography. Neuro Oncol 2009;11:861–70.
28. Kollmar O, Schilling MK, Menger MD. Experimental liver metastasis:
standards for local cell implantation to study isolated tumor growth in
mice. Clin Exp Metastasis 2004;21:453–60.
29. Mulder WJ, Castermans K, van Beijnum JR, et al. Molecular imaging
of tumor angiogenesis using alphavbeta3-integrin targeted multimodal
quantum dots. Angiogenesis 2009;12:17–24.
30. Sancey L, Garanger E, Foillard S, et al. Clustering and internalization
of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol
Ther 2009;17:837–43.
31. Ishizawa T, Fukushima N, Shibahara J, et al. Real-Time identification
of liver cancers by using indocyanine green fluorescent imaging. Can-
cer 2009;115:2491–504.
